Prof. Paul Nathan is an internationally renowned consultant medical oncologist with HCA Healthcare at LOC, The Harley Street Clinic, and The Wellington Hospital. His NHS practice is based at Mount Vernon Cancer Centre and University College London Hospitals (UCLH). Prof. Nathan's clinical interests include melanoma of the skin, eye, and internal organs; kidney cancer (renal cell carcinoma), and rare skin cancers including Merkel cell carcinoma.

Prof. Nathan originally trained in cancer immunology as a scientist. Following his Ph.D. and a post-doctoral position in Pittsburgh, he ran a tumour immunology laboratory in the pharmaceutical industry. He then pursued clinical studies at Cambridge and UCL. Prof. Nathan has been a Consultant Medical Oncologist for over 20 years. He is heavily involved in research and is the lead investigator for many clinical trials, particularly in the field of immunotherapy and targeted therapies. Most recently, he has led the development of tebentafusp, the first drug proven to improve survival in advanced uveal melanoma.

Prof. Nathan has published over 150 papers, many of which are in the world's leading medical journals, and has contributed to a number of medical textbooks. He is the Chair of the UK Uveal Melanoma Guidelines group and the UK Lead for Uveal Melanoma at the International Rare Cancer Initiative. He also leads melanoma systemic therapies for the European Organisation for Research and Treatment of Cancer (EORTC) melanoma group. Previously, Prof. Nathan chaired the NCRI renal cancer clinical studies group.

Procedures and Conditions Treated
- Immunotherapy
- Targeted Therapies
- Chemotherapy
- Urological Cancer
- Kidney Cancer
- Renal Cancer
- Skin Cancer
- Melanoma

Prof. Nathan's dedication to advancing cancer treatment and his extensive research contributions make him a leading figure in the field of medical oncology.